AR113854A1 - ANTI-CXCR5 ANTIBODIES, COMPOSITIONS AND USES THEREOF - Google Patents

ANTI-CXCR5 ANTIBODIES, COMPOSITIONS AND USES THEREOF

Info

Publication number
AR113854A1
AR113854A1 ARP180103494A ARP180103494A AR113854A1 AR 113854 A1 AR113854 A1 AR 113854A1 AR P180103494 A ARP180103494 A AR P180103494A AR P180103494 A ARP180103494 A AR P180103494A AR 113854 A1 AR113854 A1 AR 113854A1
Authority
AR
Argentina
Prior art keywords
antibodies
compositions
cxcr5 antibodies
cxcr5
afucosylated
Prior art date
Application number
ARP180103494A
Other languages
Spanish (es)
Original Assignee
Pfizer
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Univ California filed Critical Pfizer
Publication of AR113854A1 publication Critical patent/AR113854A1/en

Links

Landscapes

  • Peptides Or Proteins (AREA)

Abstract

La presente proporciona anticuerpos y sus fragmentos de unión a antígeno, que específicamente se une con CXCR5. Los anticuerpos pueden ser afucosilados y exhibir mayor ADCC en comparación con los anticuerpos fucosilados por lo demás idénticos. Además incluye usos y métodos asociados de uso de los anticuerpos.The present provides antibodies and their antigen-binding fragments, which specifically bind with CXCR5. Antibodies can be afucosylated and exhibit higher ADCC compared to otherwise identical fucosylated antibodies. It also includes uses and associated methods of using the antibodies.

ARP180103494A 2017-12-01 2018-11-28 ANTI-CXCR5 ANTIBODIES, COMPOSITIONS AND USES THEREOF AR113854A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762593830P 2017-12-01 2017-12-01

Publications (1)

Publication Number Publication Date
AR113854A1 true AR113854A1 (en) 2020-06-17

Family

ID=71523236

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103494A AR113854A1 (en) 2017-12-01 2018-11-28 ANTI-CXCR5 ANTIBODIES, COMPOSITIONS AND USES THEREOF

Country Status (1)

Country Link
AR (1) AR113854A1 (en)

Similar Documents

Publication Publication Date Title
CL2021000716A1 (en) Antibody constructs for flt3 and cd3. (divisional sol. 201800269)
CO2018011804A2 (en) Flt3 chimeric receptors and methods of use thereof
CO2018011364A2 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
CR20190434A (en) Anti-lag3 antibodies
ECSP17083779A (en) IMMUNORECEPTOR BINDING AGENTS OF T-CELLS WITH GI DOMAINS AND INHIBITION MOTIVES BASED ON IMMUNORECEPTOR TYROSINE (TIGIT) AND USES THEREOF
DOP2019000165A (en) ANTI-OX40 ANTIBODIES AND ITS USES
PH12018500861A1 (en) Antibody/t-cell receptor chimeric constructs and uses thereof
NI201800055A (en) ANTIBODIES THAT SPECIFICALLY BIND PD-1 AND ITS USES.
CL2017003195A1 (en) Affinity-matured and humanized antibodies to fcrh5 and methods for their use.
CR20190199A (en) Anti-pd-1(cd279) antibodies
CO2018010538A2 (en) Specific poliovirus receptor (rvp) antibodies
CO2018010458A2 (en) Anti-tim-3 antibodies and compositions
CO2018002446A2 (en) Thymic stromal lymphopoietin (tslp) binding molecules and methods of using the molecules
ECSP18023386A (en) STROMAL THYMIC LYMPHOPOYETIN (TSLP) BINDING MOLECULES AND METHODS OF USE OF THE MOLECULES
BR112017023943A2 (en) cd3-binding heterodimeric antibodies and tumor antigens
CO2018000976A2 (en) Antibody constructs for cd70 and cd3
ECSP18000844A (en) TAU UNION ANTIBODIES
CL2017002641A1 (en) Bispecific antibody constructs against cdh3 and cd3
BR112018074468A2 (en) anti-cd40 antibodies and their uses
ECSP18000887A (en) TAU UNION ANTIBODIES
CL2017001461A1 (en) Compositions and methods for antibodies that are labeled bmp6
CO2020006453A2 (en) Anti-cxcr5 antibodies and compositions and uses thereof
CO2020012347A2 (en) Anti-hla-g antibodies and their uses.
CR20150247A (en) ANTIHEMAGLUTININE ANTIBODIES AND METHODS OF USE
BR112016007112A2 (en) ANTIBODIES THAT BINDS HUMAN ANGIOPOIETIN 2 (ANG-2), USES OF AN ANTIBODY THAT BINDS HUMAN ANGIOPOIETIN 2 (ANG-2) AND COMBINATION